Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease

Journal of Renal Nutrition

Volumn 24, Issue 3, 2014, Pages 143-150

  Adema, Aaltje Y ^a   de Borst, Martin H ^b   ter Wee, Piet M ^a   Vervloet, Marc G ^a   Hoenderop, J H ^c   Bindels, R ^c   Navis, G J ^b   Hillebrands, J L ^b   Ter Wee, P M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

CALCIUM; CALCIUM INTAKE; CHELATING AGENT; CINACALCET; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; LANTHANUM; NAPHTHALENE DERIVATIVE; PHOSPHATE INTAKE; PHOSPHORUS; POLYAMINE; SEVELAMER;

ADMINISTRATION AND DOSAGE; BLOOD; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIET; HUMAN; HYPERPHOSPHATEMIA; METABOLISM; MORTALITY; PHOSPHATE INTAKE;

CALCIUM; CALCIUM, DIETARY; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DIET; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; NAPHTHALENES; PHOSPHORUS; PHOSPHORUS, DIETARY; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899071458     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.09.001     Document Type: Review

References (104)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEngl J Med 2004, 351:1296-1305.
2. Kalantar-Zadeh K., Block G., Humphreys M.H., Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
3. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
4. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
5. Palmer S.C., Hayen A., Macaskill P., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011, 305:1119-1127.
6. Dhingra R., Sullivan L.M., Fox C.S., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
7. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
8. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
9. Gutierrez O., Isakova T., Rhee E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
10. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
11. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
12. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
13. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82:737-747.
14. Matsushita K., Mahmoodi B.K., Woodward M., et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012, 307:1941-1951.
15. Shigematsu T., Kazama J.J., Yamashita T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004, 44:250-256.
16. Nakanishi S., Kazama J.J., Nii-Kono T., et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005, 67:1171-1178.
17. Isakova T., Xie H., Yang W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
18. Titan S.M., Zatz R., Graciolli F.G., et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011, 6:241-247.
19. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007, 18:2600-2608.
20. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
21. Cupisti A., Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol 2013, 33:180-190.
22. Ketteler M., Biggar P.H. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013, 22:413-420.
23. Gonzalez-Parra E., Gracia-Iguacel C., Egido J., Ortiz A. Phosphorus and nutrition in chronic kidney disease. Int J Nephrol 2012, 2012:597605.
24. Ketteler M., Westenfeld R., Ritz E. Not all phosphate is created equal. JRen Nutr 2012, 22:592-595.
25. Block G.A., Ix J.H., Ketteler M., et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis 2013, 62:457-473.
26. Kalantar-Zadeh K., Gutekunst L., Mehrotra R., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:519-530.
27. Sigrist M.K., Chiarelli G., Lim L., Levin A. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. J Ren Care 2009, 35(suppl 1):71-78.
28. Tonelli M., Pannu N., Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010, 362:1312-1324.
29. Seiler S., Lucisano G., Ege P., et al. Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients. Clin J Am Soc Nephrol 2013, 8:1764-1772.
30. Hruska K.A., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008, 74:148-157.
31. Sigrist M., Tang M., Beaulieu M., et al. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant 2013, 28:161-169.
32. Vervloet M.G., van Ittersum F.J., Buttler R.M., Heijboer A.C., Blankenstein M.A., ter Wee P.M. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011, 6:383-389.
33. Savica V., Calo L.A., Caldarera R., et al. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol 2007, 105:52-55.
34. Savica V., Calo L., Santoro D., Monardo P., Granata A., Bellinghieri G. Salivary phosphate secretion in chronic kidney disease. J Ren Nutr 2008, 18:87-90.
35. Marks J., Debnam E.S., Unwin R.J. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010, 299:F285-F296.
36. Fouque D., Pelletier S., Mafra D., Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011, 80:348-357.
37. Boaz M., Smetana S. Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake. J Am Diet Assoc 1996, 96:1268-1270.
38. Di I.B., Di M.L., Torraca S., et al. Acute effects of very-low-protein dieton FGF23 levels: a randomized study. Clin J Am Soc Nephrol 2012, 7:581-587.
39. Levey A.S., Greene T., Beck G.J., et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999, 10:2426-2439.
40. Shinaberger C.S., Greenland S., Kopple J.D., et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr 2008, 88:1511-1518.
41. Lynch K.E., Lynch R., Curhan G.C., Brunelli S.M. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:620-629.
42. Cupisti A., Benini O., Ferretti V., Gianfaldoni D., Kalantar-Zadeh K. Novel differential measurement of natural and added phosphorus in cooked ham with or without preservatives. J Ren Nutr 2012, 22:533-540.
43. Sullivan C., Sayre S.S., Leon J.B., et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009, 301:629-635.
44. Schlemmer U., Frolich W., Prieto R.M., Grases F. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res 2009, 53(suppl 2):S330-S375.
45. Moe S.M., Chen N.X., Seifert M.F., et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009, 75:176-184.
46. Moe S.M., Zidehsarai M.P., Chambers M.A., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:257-264.
47. Scialla J.J., Appel L.J., Wolf M., et al. Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. JRen Nutr 2012, 22:379-388.
48. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
49. Oenning L.L., Vogel J., Calvo M.S. Accuracy of methods estimating calcium and phosphorus intake in daily diets. J Am Diet Assoc 1988, 88:1076-1080.
50. Mathewson A.M., Fouque D., Toft A.J. Dietary phosphate assessment in dialysis patients. J Ren Nutr 2010, 20:351-358.
51. Savica V., Calo L.A., Monardo P., et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 2009, 20:639-644.
52. Isakova T., Gutierrez O.M., Chang Y., et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009, 20:388-396.
53. Kovesdy C.P., Kuchmak O., Lu J.L., Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010, 56:842-851.
54. Navaneethan S.D., Palmer S.C., Craig J.C., Elder G.J., Strippoli G.F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 54:619-637.
55. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
56. Guerin A.P., London G.M., Marchais S.J., Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000, 15:1014-1021.
57. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
58. Tentori F., Blayney M.J., Albert J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519-530.
59. Young E.W., Akiba T., Albert J.M., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004, 44:34-38.
60. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
61. Kovesdy C.P., Kalantar-Zadeh K. Serum phosphorus and the risk of progression of chronic kidney disease. Nephrol Dial Transplant 2007, 22:3679-3680.
62. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
63. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62:245-252.
64. Chertow G.M., Raggi P., McCarthy J.T., et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003, 23:307-314.
65. Braun J., Asmus H.G., Holzer H., et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004, 62:104-115.
66. Asmus H.G., Braun J., Krause R., et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005, 20:1653-1661.
67. Qunibi W., Moustafa M., Muenz L.R., et al. A 1-year randomized trial ofcalcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008, 51:952-965.
68. Barreto D.V., Barreto F.C., de Carvalho A.B., et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008, 110:c273-c283.
69. Block G.A., Wheeler D.C., Persky M.S., et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012, 23:1407-1415.
70. Zhang Q., Li M., Lu Y., et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 2010, 115:c259-c267.
71. Winkelmayer W.C., Liu J., Kestenbaum B. Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. Clin J Am Soc Nephrol 2011, 6:175-183.
72. Tonelli M., Wiebe N., Culleton B., et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007, 22:2856-2866.
73. Jamal S.A., Fitchett D., Lok C.E., Mendelssohn D.C., Tsuyuki R.T. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009, 24:3168-3174.
74. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
75. Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
76. Di I.B., Bellasi A., Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012, 7:487-493.
77. Oliveira R.B., Cancela A.L., Graciolli F.G., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
78. Isakova T., Gutierrez O.M., Smith K., et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26:584-591.
79. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011, 26:2567-2571.
80. Isakova T., Barchi-Chung A., Enfield G., et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013, 8:1009-1018.
81. Yilmaz M.I., Sonmez A., Saglam M., et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012, 59:177-185.
82. Bleskestad I.H., Bergrem H., Hartmann A., Godang K., Goransson L.G. Fibroblast growth factor 23 and parathyroid hormone after treatment withactive vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol 2012, 13:49.
83. Spatz C., Roe K., Lehman E., Verma N. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract 2013, 123:61-66.
84. Koiwa F., Kazama J.J., Tokumoto A., et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005, 9:336-339.
85. Cancela A.L., Oliveira R.B., Graciolli F.G., et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011, 117:c74-c82.
86. Evenepoel P., Viaene L., Meijers B. PTH, FGF23, and calcium: it takes three to tango?. Kidney Int 2011, 80:1377.
87. Shimada T., Yamazaki Y., Takahashi M., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005, 289:F1088-F1095.
88. Rodriguez-Ortiz M.E., Lopez I., Munoz-Castaneda J.R., et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012, 23:1190-1197.
89. Drueke T.B. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000, 11:1141-1152.
90. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010, 77:292-298.
91. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
92. Kazama J.J., Sato F., Omori K., et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005, 67:1120-1125.
93. Krajisnik T., Olauson H., Mirza M.A., et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010, 78:1024-1032.
94. Sun C.Y., Chang S.C., Wu M.S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012, 81:640-650.
95. Komaba H., Goto S., Fujii H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010, 77:232-238.
96. Sato T., Tominaga Y., Ueki T., et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004, 44:481-487.
97. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004, 350:1516-1525.
98. Fukagawa M., Yumita S., Akizawa T., et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008, 23:328-335.
99. Fishbane S., Shapiro W.B., Corry D.B., et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008, 3:1718-1725.
100. Komaba H., Nakanishi S., Fujimori A., et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010, 5:2305-2314.
101. Wetmore J.B., Liu S., Krebill R., Menard R., Quarles L.D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010, 5:110-116.
102. Hryszko T., Brzosko S., Rydzewska-Rosolowska A., Koc-Zorawska E., Mysliwiec M. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol 2012, 44:1479-1486.
103. Ito M., Sakai Y., Furumoto M., et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 2005, 288:E1101-E1109.
104. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.